Orbactiv
Communicable Diseases, Gram-Positive Bacterial Infections
Treatment
0 Active Studies for Orbactiv
Treatment for
Communicable Diseases
What is Orbactiv
Oritavancin
The Generic name of this drug
Treatment Summary
Oritavancin is an antibiotic used to treat skin infections caused by certain types of bacteria. It was first approved by the FDA in 2014 and is given as a single dose, which has been shown to be as effective as a full course of vancomycin. In 2021, the FDA approved Kimyrsa, a new form of oritavancin that can be taken in a single, one-hour infusion, compared to the three-hour infusion of Orbactiv, another brand of oritavancin.
Orbactiv
is the brand name
Orbactiv Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Orbactiv
Oritavancin
2014
4
Effectiveness
How Orbactiv Affects Patients
Oritavancin is an antibiotic used to treat infections of the skin and subcutaneous tissue caused by certain types of bacteria. It works by disrupting the cell walls of the bacteria. This drug can also interfere with certain blood clotting tests and cause allergic reactions.
How Orbactiv works in the body
Oritavancin is an antibiotic that targets bacteria by disrupting the cell wall and membrane. It binds to specific parts of the cell wall, stopping it from forming or growing properly. This prevents the bacteria from replicating, leading to its death. Oritavancin also disrupts the cell membrane, interfering with its integrity and eventually killing the bacteria.
When to interrupt dosage
The amount of Orbactiv is dependent upon the diagnosed ailment. The dosage is contingent upon the administration technique featured in the table below.
Condition
Dosage
Administration
Gram-Positive Bacterial Infections
, 400.0 mg, 120.0 mg/mL
, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Communicable Diseases
, 400.0 mg, 120.0 mg/mL
, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Warnings
Orbactiv has two contraindications, thus it should not be employed in the presence of the conditions outlined in the following table.
Orbactiv Contraindications
Condition
Risk Level
Notes
Pulse Frequency
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Oritavancin may interact with Pulse Frequency
There are 20 known major drug interactions with Orbactiv.
Common Orbactiv Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The metabolism of Abemaciclib can be increased when combined with Oritavancin.
Acalabrutinib
Major
The metabolism of Acalabrutinib can be increased when combined with Oritavancin.
Alectinib
Major
The metabolism of Alectinib can be increased when combined with Oritavancin.
Alpelisib
Major
The metabolism of Alpelisib can be increased when combined with Oritavancin.
Aminophylline
Major
The metabolism of Aminophylline can be increased when combined with Oritavancin.
Orbactiv Toxicity & Overdose Risk
The lowest toxic dose of oritavancin in rats is greater than 500mg/kg. No overdoses have been reported during clinical testing, but an overdose could lead to headache, nausea, vomiting, and diarrhea. Since this drug cannot be removed by dialysis, supportive measures should be taken if an overdose occurs.
Orbactiv Novel Uses: Which Conditions Have a Clinical Trial Featuring Orbactiv?
At present, zero studies are investigating the potential of Orbactiv to treat Gram Positive Bacterial Infections.
Condition
Clinical Trials
Trial Phases
Communicable Diseases
0 Actively Recruiting
Gram-Positive Bacterial Infections
0 Actively Recruiting
Patient Q&A Section about orbactiv
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Does Orbactiv cover MRSA?
"The FDA approved Orbactiv for the treatment of adults with acute bacterial skin and skin structure infections (ABSSSIs) caused by susceptible designated Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) in August 2014."
Answered by AI
What is oritavancin used to treat?
"Oritavancin is an antibiotic injection used to treat acute bacterial skin and skin structure infections (ABSSSI). Oritavancin works by killing bacteria or preventing their growth. It will not work for colds, flu, or other virus infections."
Answered by AI
How do you administer Orbactiv?
"The recommended dosage of ORBACTIV is 1,200 mg given as a single dose by intravenous infusion over 3 hours for patients 18 years and older. See Warnings and Precautions (5.3) for more information."
Answered by AI
What is Orbactiv used for?
"ORBACTIV may be a better option than vancomycin for treating adult patients with ABSSSI caused by indicated pathogens."
Answered by AI